Clinical trial
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic…
NCT00019656 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019656 |
|---|---|
| Title | Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer |
| Official title | A Phase I Trial of Oral Perifosine With Different Loading Schedules in Patients With Refractory Neoplasms |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | perifosine |
| Start date | Aug 1, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: